跳至主要内容
临床试验/NCT00428701
NCT00428701已完成4 期

An Open-Label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium I.V. (Esomeprazole Sodium) 40mg BID for up to 72 Hours

AstraZeneca5 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2006年10月最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
AstraZeneca
入组人数
40
试验地点
5
主要终点
The primary objective of the study is to assess gastric acid suppression by esomeprazole iv in critically ill subjects

研究概览

简要总结

This study is being done to see if Nexium I.V. can reduce and control stomach acid in mechanically ventilated, critically ill patients in an Intensive Care Unit setting.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Critically ill male or female subjects 18 years or older who have a baseline gastric aspirate pH less then or equal to 4
  • Subjects admitted to an ICU requiring mechanically ventilated
  • Subjects will have at least one additional stress ulcer risk factor

排除标准

  • Anticipated use of pre-pyloric enteral feeding after screening until the end of study
  • Physician estimated survival of less then 96 hours
  • Anticipation of major surgery within 96 hours of study enrollment

结局指标

主要结局

The primary objective of the study is to assess gastric acid suppression by esomeprazole iv in critically ill subjects

次要结局

  • The secondary objective is to assess time to stable pH greater then or equal to 4 from start of drug

研究者

发起方
AstraZeneca
申办方类型
Industry

研究点 (5)

Loading locations...

相似试验